BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3258143)

  • 21. beta-Lactamase activities and resistance to antibiotics of Haemophilus influenzae, H. parainfluenzae and H. aphrophilus strains identified in throat cultures from children.
    Uraz G; Simşek H; Celik B
    Drug Metabol Drug Interact; 2000; 16(3):217-28. PubMed ID: 11116755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Smith SM
    Antimicrob Agents Chemother; 1986 Feb; 29(2):325-6. PubMed ID: 2940966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
    Hooper DC; Wolfson JS
    Antimicrob Agents Chemother; 1985 Nov; 28(5):716-21. PubMed ID: 2936302
    [No Abstract]   [Full Text] [Related]  

  • 26. Quinolones.
    Shah PM
    Prog Drug Res; 1987; 31():243-56. PubMed ID: 3326031
    [No Abstract]   [Full Text] [Related]  

  • 27. Typing of urogenital, maternal, and neonatal isolates of Haemophilus influenzae and Haemophilus parainfluenzae in correlation with clinical source of isolation and evidence for a genital specificity of H. influenzae biotype IV.
    Quentin R; Musser JM; Mellouet M; Sizaret PY; Selander RK; Goudeau A
    J Clin Microbiol; 1989 Oct; 27(10):2286-94. PubMed ID: 2584379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
    Grimm H
    Infection; 1986; 14 Suppl 3():S191-5. PubMed ID: 3093387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI; Dabbs DJ; Spencer RC
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.
    Chin NX; Novelli A; Neu HC
    Antimicrob Agents Chemother; 1988 May; 32(5):656-62. PubMed ID: 3164987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of five fluoroquinolones against Mycobacterium avium-intracellulare complex and M. xenopi.
    Rastogi N; Goh KS; David HL
    Ann Inst Pasteur Microbiol; 1988; 139(2):233-7. PubMed ID: 3165641
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
    Periti P; Mazzei T; Nicoletti P
    Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fluoroquinolones].
    Baykal M; Akalin E
    Mikrobiyol Bul; 1987 Apr; 21(2):151-7. PubMed ID: 3482120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of the 4-quinolones.
    Eggleston M; Park SY
    Infect Control; 1987 Mar; 8(3):119-25. PubMed ID: 3553053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens.
    Liebowitz LD; Saunders J; Fehler G; Ballard RC; Koornhof HJ
    Antimicrob Agents Chemother; 1986 Dec; 30(6):948-50. PubMed ID: 3101590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.